Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Understandably there is little appetite to scrutinise much of what has occurred at the moment for fear of distraction.
The latest debacle with a lab just set up with the apparent sole purpose to profiteer in a crisis just goes to show you can magically be awarded £100s of millions of public money without established expertise or competence.
Very wiffy smells around many of these mega deals with no transparency.
Much better to present our wares worldwide than be constricted by governmental halfhearted schemes, unqualified favouritism and chaos imho.
Steady, my tuppence worth is to steer well clear of Agile - a most unfortunate name.
Look at the drag effect the DHSC dispute has had on the NCYT share price, despite NCYT continuing to supply them and having millions in cash.
Then there is Prof Horby and his hopeless "recovery" trial. It only managed to "find" Dexamethasone, a ready available drug, despite Synairgen having stonking P2 results. P3 results have now been delayed until 2022, in the middle of a pandemic when people are dying!!
Then the Government stockpiled the cheap, inaccurate LFT's from China, meanwhile Han**** was busy destroying his marriage.
The ODX saga has already been mentioned on this thread.
Keep the inept UK Government out of it and leave the commercial pharmas to get things done.
Takeover is my preferred option.
ndr50 ... the NOMAD advises the board on disclosure issues and they make the call ... and take the risk of not doing so ... most AIM companies do not have the capacity or expertise to make such decisions ... hence the need for a NOMAD
Surely if phase 1 and 2 have already begun for Covid BOD have duty to inform market and shareholders. Seems absurd that such trials could be ongoing without being in public domain.
Steady, I think the 1st HNWI saw the data on covid, sat down with the BOD and told them to cold shoulder AGILE as more lucrative to go it alone and in other indications and then got his/her mates to invest futher to take the funding to £4.5m as part of the push to take both 1801 snd 1802 into clinic.
Just my opinion but remember they invested £1.4m 2wks prior to the covid research update on 01 July so might well have said 'look give Agile the boot and we'll raise the funds go it alone and have another crack at bacterial pneumonia as well and if we crack it then 50bags for us all and we make a little bit of history in the process and at worst 10bags and at least we got to clinic and had patents in place and gave the majors the sh.ts as we have no tox issues all the way in pre-clinical so they had to licence us up prior to ph2".
Having been in ODX all I can say the further the government is removed from SAR the more comfortable I feel.
That's what I think Danny so if I am right it shows our bod are looking for the best value ... And that is encouraging
Hi Mafuta. I think I should have ended my point re Agile as per subscriptions better. I'm of the opinion that the subscriptions are because we will go our own way. Self funded.
Danny I feel the agile route is dead in the water ... The conditions attached must have various strings and restrictions attached ... As much as it may irritate some the bod will want to see the best commercial outcome and will want to sell the IP to the highest bidder ... So that precludes government involvement ... Hence enter the HNWIs stage left ... Beat regards Mafuta
I couldn’t see the government backing something for the company to say we have encouraging results and then knock it on the head especially in a pandemic which is still going and judging by the figures starting to get worse again even after vaccinations as I’ve mentioned before I’m a firm believer they have already put 1801 into trails and I know people scoff but it was used in P1 P2 trials lupus which Covid has been strongly linked too through scientific evidence
Purely my own opinion but nothing has come out since the 1st July statement and who honestly expected this silence for so long ?
GLA
Come on the SAR
Steadydanny I think the longer the wait for agile goes on the less likely it’s going to happen. The main reason that has been given on this bb is the financial implications of using agile. Let’s hope it is for that reason and not for a lack of interest in utilising 1801 as a treatment.
We noted dec 2020 and said 6 months
Quote
SDC-1801 – Covid-19 studies
The UKRI-funded Covid-19 research project for SDC-1801 is expected to complete on schedule with the experimental phases finishing in June and the data analysis to complete shortly thereafter. The Company will provide a further update once the relevant data are available.
As noted in the Interim Results, initial results from this research are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2.
If the completed studies are successful, the Company plans to explore the possibility for further UK government funding from the recently launched AGILE clinical development platform, which has been established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development...
Then Mr Reader says
Dr John Reader, CSO of Sareum, commented:
“The results from our Covid-19 research project are very encouraging and provide clear evidence of the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. We are keen to progress this project to the next stage and will now explore our options to find the best way to fund these next steps. This could include the UK government’s AGILE clinical development platform, which was established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan targeting autoimmune diseases. We look forward to providing updates on our progress as we reach key milestones in the development of SDC-1801.”
The Grant for the project was awarded to Sareum through the Innovate UK Sustainable Innovation Fund for projects that address and mitigate the health, social, cultural and environmental impacts of the Covid-19 outbreak.
Given all the talk of Agile anyone think it a little bit coincidental the following RNSs were subscriptions..aka 'could include Agile.'
Just a muse.
I might go for an amuse bouche